Bmf Antibody

Blue Ice

Predicted: 20 kDa
Observed: 22 kDa

Bmf Antibody: Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor). The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program. Bmf is constitutively expressed in many tissues.

Trial Size

15723378

PRS-1210-0.1mg

PRS-1201-0.1mg

1 mg/mL

Bmf antibody can be used for detection of Bmf by Western blot at 1 - 2 μ g/mL. Antibody can also be used for immunocytochemistry starting at 10 μ g/mL. For immunofluorescence start at 5 μ g/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Bmf antibody was raised with a synthetic peptide corresponding to 15 amino acids near the amino terminus of human Bmf.

The immunogen is located within the first 50 amino acids of Bmf.

Bcl2 modifying factor

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.